Erasca, Inc. (ERAS) shareholders
Close on Nov 17, 2026Market cap $4.86BP/E –Yield 0.00%
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Jonathan E. Lim Joint filing with Conyee T. Lim (5.60%) | 36,968,486 | 10.40% | 13G (passive) amendment | Jun 30, 2026 |
| Patrick J. Heron Joint filing with James N. Topper (8.00%), Albert Cha (6.10%) and 4 more | 22,575,851 | 8.00% | 13G (passive) amendment | Mar 31, 2025 |
| T. Rowe Price Investment Management, Inc. | 21,224,264 | 6.80% | 13G (passive) amendment | Mar 31, 2026 |
| Venrock Healthcare Capital Partners EG, L.P. Joint filing with Venrock Healthcare Capital Partners III, L.P. (5.30%), VHCP Co-Investment Holdings III, LLC (5.30%) and 4 more | 16,382,812 | 5.30% | 13G (passive) amendment | Mar 31, 2026 |
| Roderick Wong Joint filing with RTW Investments, LP (5.20%) | 16,157,175 | 5.20% | 13G (passive) | Mar 31, 2026 |
| BlackRock, Inc. | 15,358,280 | 5.40% | 13G (passive) | Sep 30, 2024 |
| Arsani William Joint filing with Logos Global Management LP (5.30%), Logos Global Management GP LLC (5.30%) | 15,100,000 | 5.30% | 13G (passive) | Jun 30, 2025 |
| Frazier Life Sciences Public Fund, L.P. Joint filing with Fhmlsp, L.P. (5.30%), Fhmlsp, L.L.C. (5.30%) | 15,038,753 | 5.30% | 13G (passive) amendment | Jun 30, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ERAS | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 24,975,188 | 7.14% | $457.55M | +300,000 | 9.96% |
| T. Rowe Price Investment Management, Inc. | 21,185,839 | 6.06% | $388.13M | −73,807 | 0.25% |
| BlackRock, Inc. | 21,154,146 | 6.05% | $387.54M | +1,002,740 | 0.01% |
| Rtw Investments, LP | 17,946,754 | 5.13% | $328.78M | +1,789,579 | 2.81% |
| VR Adviser, LLC | 17,891,812 | 5.12% | $327.78M | +1,509,000 | 9.94% |
| State Street Corp | 12,184,555 | 3.48% | $223.22M | +2,884,471 | 0.01% |
| Logos Global Management LP | 12,150,000 | 3.47% | $222.59M | +1,000,000 | 9.58% |
| Vanguard Capital Management LLC | 11,402,199 | 3.26% | $208.89M | +152,461 | 0.00% |
| Siren, L.L.C. | 11,397,781 | 3.26% | $208.81M | +153,535 | 4.23% |
| Paradigm Biocapital Advisors LP | 9,550,000 | 2.73% | $174.96M | −842,702 | 3.28% |
| ARCH Venture Management, LLC | 7,091,557 | 2.03% | $129.92M | – | 11.81% |
| Geode Capital Management, LLC | 6,501,426 | 1.86% | $119.13M | +505,277 | 0.01% |
| Price T Rowe Associates Inc /Md/ | 6,272,508 | 1.79% | $114.91M | +4,457,168 | 0.01% |
| Cormorant Asset Management, LP | 6,000,000 | 1.72% | $109.92M | +200,000 | 5.63% |
| Affinity Asset Advisors, LLC | 5,250,000 | 1.50% | $96.18M | −100,000 | 4.35% |
| Vivo Capital, LLC | 4,127,412 | 1.18% | $75.61M | −8,024,068 | 6.90% |
| Alliancebernstein L.P. | 4,118,614 | 1.18% | $66.64M | +1,473,694 | 0.02% |
| Goldman Sachs Group Inc | 3,822,113 | 1.09% | $70.02M | −1,053,073 | 0.01% |
| Bank Of America Corp /De/ | 3,048,737 | 0.87% | $55.85M | −7,160 | 0.00% |
| FMR LLC | 2,883,417 | 0.82% | $52.82M | +1,393,337 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 257 | 281M | 80.4% | 63 / 102 | 77 / 27 | 46M | 35M |
| Q1 2026 | 225 | 274M | 78.3% | 97 / 77 | 39 / 23 | 100M | 38M |
| Q4 2025 | 154 | 224M | 64.1% | 32 / 45 | 46 / 18 | 18M | 10M |
| Q3 2025 | 141 | 216M | 61.8% | 17 / 41 | 43 / 16 | 9M | 11M |
| Q2 2025 | 142 | 219M | 62.5% | 25 / 59 | 38 / 36 | 16M | 22M |
| Q1 2025 | 154 | 224M | 64.1% | 28 / 49 | 47 / 18 | 9M | 15M |
| Q4 2024 | 146 | 231M | 66.0% | 27 / 52 | 39 / 12 | 15M | 18M |
| Q3 2024 | 132 | 234M | 66.9% | 26 / 53 | 30 / 18 | 61M | 28M |
| Q2 2024 | 126 | 212M | 60.5% | 39 / 51 | 24 / 20 | 151M | 14M |
| Q1 2024 | 108 | 74M | 21.2% | 20 / 30 | 44 / 31 | 13M | 9M |
| Q4 2023 | 119 | 70M | 20.0% | 28 / 42 | 34 / 14 | 16M | 15M |
| Q3 2023 | 109 | 71M | 20.4% | 9 / 49 | 29 / 12 | 3M | 6M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
234 funds held ERAS in Q2 2026, 45% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of ERAS | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 8,384,454 | 2.40% | $153.60M | 0.01% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 7,447,165 | 2.13% | $136.43M | 1.27% | Jun 30, 2026 |
| T. Rowe Price Capital Appreciation Fund | 6,954,600 | 1.99% | $127.41M | 0.18% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 5,137,080 | 1.47% | $94.11M | 0.11% | Jun 30, 2026 |
| T. Rowe Price Small-Cap Stock Fund, Inc. | 3,334,921 | 0.95% | $61.10M | 0.66% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 2,746,433 | 0.79% | $50.31M | 0.05% | Jun 30, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 2,584,513 | 0.74% | $47.35M | 0.40% | Jun 30, 2026 |
| Select Biotechnology Portfolio | 2,533,680 | 0.72% | $32.53M | 0.62% | May 31, 2026 |
| Fidelity Small Cap Index Fund | 2,409,217 | 0.69% | $43.73M | 0.13% | Jul 31, 2026 |
| T. Rowe Price Institutional Small-Cap Stock Fund | 1,786,568 | 0.51% | $32.73M | 0.65% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 1,667,210 | 0.48% | $30.54M | 0.20% | Jun 30, 2026 |
| JNL/T. Rowe Price Capital Appreciation Fund | 1,523,521 | 0.44% | $27.91M | 0.18% | Jun 30, 2026 |
| T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund | 1,435,300 | 0.41% | $26.29M | 0.27% | Jun 30, 2026 |
| Victory Pioneer Select Mid Cap Growth Fund | 1,332,535 | 0.38% | $17.11M | 0.90% | May 31, 2026 |
| iShares Biotechnology ETF | 1,325,097 | 0.38% | $24.28M | 0.27% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Jonathan E. Lim | Chairman & CEO, Director, 10% owner | 32,355,576 | 9.25% | Jan 30, 2026 |
| Charles S. Fuchs | President, R&D | – | – | Aug 12, 2026 |
| Ebun Garner | Chief Legal Officer | 105,076 | 0.03% | Apr 3, 2026 |
| Shannon Morris | Chief Medical Officer | 20,000 | 0.01% | Mar 6, 2026 |
| David M. Chacko | CFO and CBO | 279,980 | 0.08% | Jan 30, 2026 |
| Pratik S. Multani | Director | 172,866 | 0.05% | Jun 29, 2026 |
| Julie Hambleton | Director | 6,000 | 0.00% | Jun 29, 2026 |
| Valerie Denise Harding Start | Director | 22,000 | 0.01% | Jun 29, 2026 |
| Alexander W. Casdin | Director | 667,724 | 0.19% | Jun 29, 2026 |
| James Arthur Bristol | Director | 207,500 | 0.06% | Jun 29, 2026 |
| Jean I. Liu | Director | – | – | Jun 29, 2026 |
| Michael David Varney | Director | – | – | Jan 30, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Ebun Garner Chief Legal Officer | Apr 1, 2026 | Option exercise | +80,000 | $1.70 | $136.00K | 105,076 |
| Ebun Garner Chief Legal Officer | Apr 1, 2026 | Sale(10b5-1 plan) | −80,000 | $16.40 | $1.31M | 25,076 |
| Shannon Morris Chief Medical Officer | Mar 4, 2026 | Option exercise | +20,000 | $1.70 | $34.00K | 20,000 |
| Shannon Morris Chief Medical Officer | Mar 4, 2026 | Sale(10b5-1 plan) | −20,000 | $15.04 | $300.80K | 0 |
| Ebun Garner General Counsel & Corp. Sec. | Jan 7, 2026 | Option exercise | +120,000 | $1.70 | $204.00K | 145,076 |
| Ebun Garner General Counsel & Corp. Sec. | Jan 7, 2026 | Sale(10b5-1 plan) | −120,000 | $5.59 | $670.80K | 25,076 |
| David M. Chacko CFO and CBO | Dec 15, 2025 | Other | +17,793 | $1.19 | $21.17K | 279,980 |
| Ebun Garner General Counsel & Corp. Sec. | Dec 15, 2025 | Award | +3,902 | $1.19 | $4.64K | 25,076 |
| Pratik S. Multani Director | May 23, 2025 | Gift | −6,200 | – | – | 166,666 |
| Pratik S. Multani Director | May 23, 2025 | Gift | +6,200 | – | – | 6,200 |
| David M. Chacko CFO and CBO | Dec 13, 2024 | Other | +12,324 | $1.56 | $19.23K | 262,187 |
| Ebun Garner General Counsel & Corp. Sec. | Dec 13, 2024 | Other | +5,731 | $1.56 | $8.94K | 21,174 |
| David M. Chacko CFO and CBO | Jun 14, 2024 | Other | +3,137 | $1.56 | $4.89K | 262,187 |
| Ebun Garner General Counsel & Corp. Sec. | Jun 14, 2024 | Other | +5,715 | $1.56 | $8.92K | 21,174 |
| Alexander W. Casdin Director | May 21, 2024 | Buy | +80,000 | $2.27 | $181.60K | 573,974 |
| David M. Chacko CFO and CBO | Dec 15, 2023 | Other | +7,478 | $1.59 | $11.89K | 246,726 |
| Ebun Garner General Counsel & Corp. Sec. | Dec 15, 2023 | Other | +5,448 | $1.59 | $8.66K | 9,728 |
| Valerie Denise Harding Start Director | Dec 6, 2023 | Buy | +10,000 | $1.85 | $18.50K | 20,000 |
| Jonathan E. Lim Chairman & CEO, Director, 10% owner | Dec 6, 2023 | Buy | +278,150 | $1.72 | $478.42K | 12,899,360 |
| Jonathan E. Lim Chairman & CEO, Director, 10% owner | Dec 5, 2023 | Buy | +721,850 | $1.69 | $1.22M | 12,899,360 |
| Alexander W. Casdin Director | Dec 4, 2023 | Buy | +30,000 | $1.66 | $49.80K | 493,974 |
| Jonathan E. Lim Chairman & CEO, Director, 10% owner | Oct 5, 2023 | Buy | +1,000,000 | $2.03 | $2.03M | 19,456,216 |
| Jonathan E. Lim Chairman & CEO, Director, 10% owner | Jun 8, 2023 | Buy | +100,000 | $2.75 | $275.00K | 18,396,216 |
| Alexander W. Casdin Director | Apr 10, 2023 | Buy | +20,000 | $2.76 | $55.20K | 463,974 |
| Jonathan E. Lim Chairman & CEO, Director, 10% owner | Mar 28, 2023 | Buy | +100,000 | $2.84 | $284.00K | 18,296,216 |
| Ebun Garner General Counsel & Corp. Sec. | Feb 1, 2023 | Other | +2,388 | $4.10 | $9.79K | 4,280 |
| Ebun Garner General Counsel & Corp. Sec. | Feb 1, 2023 | Other | +2 | $3.89 | $8 | 4,280 |
| Lin Wei Chief Medical Officer | Feb 1, 2023 | Other | +1,748 | $4.10 | $7.17K | 315,812 |
| Lin Wei Chief Medical Officer | Feb 1, 2023 | Other | +2 | $3.89 | $8 | 315,812 |
| David M. Chacko Chief Financial Officer | Feb 1, 2023 | Other | +2 | $3.89 | $8 | 239,248 |
| David M. Chacko Chief Financial Officer | Feb 1, 2023 | Other | +1,748 | $4.10 | $7.17K | 239,248 |
| Jonathan E. Lim Chairman & CEO, Director, 10% owner | Jan 10, 2023 | Buy | +60,000 | $3.86 | $231.60K | 20,256,222 |
| Valerie Denise Harding Start Director | Dec 21, 2022 | Buy | +10,000 | $4.64 | $46.40K | 10,000 |
| James Arthur Bristol Director | Dec 21, 2022 | Buy | +20,000 | $4.14 | $82.80K | 20,000 |
| Alexander W. Casdin Director | Dec 15, 2022 | Buy | +20,000 | $4.87 | $97.40K | 443,974 |
| Jonathan E. Lim Chairman & CEO, Director, 10% owner | Dec 14, 2022 | Buy | +40,000 | $4.99 | $199.60K | 20,196,222 |
| Cormorant Asset Management, LP Director | Dec 13, 2022 | Buy | +307,692 | $6.50 | $2.00M | 10,813,246 |
| Cormorant Asset Management, LP Director | Dec 13, 2022 | Buy | +307,692 | $6.50 | $2.00M | 10,813,246 |
| Jonathan E. Lim Chairman and CEO, Director, 10% owner | Nov 30, 2022 | Gift | −2,000,006 | – | – | 18,196,216 |
| Alexander W. Casdin Director | Jul 1, 2022 | Other | −750,000 | – | – | 0 |
| Lin Wei Chief Medical Officer | Feb 1, 2022 | Other | +1,562 | $11.60 | $18.12K | 314,062 |
| David M. Chacko Chief Financial Officer | Feb 1, 2022 | Other | +1,562 | $11.60 | $18.12K | 237,498 |
| Ebun Garner General Counsel & Corp. Sec. | Feb 1, 2022 | Other | +990 | $11.60 | $11.48K | 1,890 |
| Bihua Chen Director | Aug 10, 2021 | Buy | +200,000 | $22.10 | $4.42M | 10,505,553 |
| Bihua Chen Director | Jul 26, 2021 | Sale | −200,000 | $18.77 | $3.75M | 10,305,553 |
| Cormorant Asset Management, LP 10% owner | Jul 20, 2021 | Buy | +950,000 | $16.00 | $15.20M | 10,505,553 |
| Cormorant Asset Management, LP 10% owner | Jul 20, 2021 | Conversion | +9,555,553 | – | – | 9,555,553 |
| Alexander W. Casdin Director | Jul 20, 2021 | Conversion | +150,000 | – | – | 337,500 |
| Alexander W. Casdin Director | Jul 20, 2021 | Conversion | +750,000 | – | – | 750,000 |
| Kristina Burow 10% owner | Jul 20, 2021 | Conversion | +5,527,777 | – | – | 5,527,777 |
| Kristina Burow 10% owner | Jul 20, 2021 | Conversion | +5,527,777 | – | – | 5,527,777 |
| Valerie Denise Harding Start Director | Jul 20, 2021 | Buy | +2,000 | $16.00 | $32.00K | 2,000 |
| Pratik S. Multani Director | Jul 20, 2021 | Buy | +6,200 | $16.00 | $99.20K | 172,866 |
| Julie Hambleton Director | Jul 20, 2021 | Buy | +6,000 | $16.00 | $96.00K | 6,000 |
| City Hill, LLC 10% owner | Jul 20, 2021 | Conversion | +5,135,390 | – | – | 20,156,222 |
| City Hill, LLC 10% owner | Jul 20, 2021 | Conversion | +5,441,027 | – | – | 11,899,360 |
| Ebun Garner General Counsel | Jul 20, 2021 | Buy | +900 | $16.00 | $14.40K | 900 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Erasca's stock actually held short. Settlement fails (shares not delivered on time) peaked at 111,483 shares on Sep 29, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Erasca Foundation Foundation | Oct 15, 2026 | 8,333 | $122.35K | Oct 15, 2026 | Donation |
| Erasca Foundation Foundation | Sep 15, 2026 | 8,333 | $133.09K | Sep 15, 2026 | Donation |
| Erasca Foundation Foundation | Aug 17, 2026 | 8,333 | $152.42K | Aug 17, 2026 | Donation |
| Erasca Foundation Foundation | Jul 21, 2026 | 8,333 | $157.64K | Jul 21, 2026 | Donation |
| Erasca Foundation Foundation | Jun 15, 2026 | 8,333 | $117.48K | Jun 15, 2026 | Donation |
| Erasca Foundation Foundation | May 15, 2026 | 8,333 | $84.53K | May 15, 2026 | Donation |
| Erasca Foundation Foundation | Apr 15, 2026 | 8,333 | $150.84K | Apr 15, 2026 | Donation |
| Erasca Foundation Foundation | Apr 15, 2026 | 8,333 | $150.84K | Apr 15, 2026 | Donation |
| Ebun Garner Officer | Apr 1, 2026 | 80,000 | $1.31M | Apr 1, 2026 | Stock Option |
| Erasca Foundation Foundation | Mar 16, 2026 | 8,333 | $116.86K | Mar 16, 2026 | Donation |
| Shannon Morris Officer | Mar 4, 2026 | 20,000 | $300.77K | Mar 4, 2026 | Stock Option |
| Erasca Foundation Foundation | Feb 17, 2026 | 8,333 | $99.25K | Feb 17, 2026 | Donation |
| Erasca Foundation Foundation | Jan 15, 2026 | 8,333 | $68.57K | Jan 15, 2026 | Donation |
| Ebun Garner Officer | Jan 7, 2026 | 120,000 | $670.81K | Jan 7, 2026 | Stock Option |
| Erasca Foundation Foundation | Dec 15, 2025 | 8,333 | $30.44K | Dec 15, 2025 | Donation |
See a number that looks wrong?